Gesynta Pharma AB was founded in 2017 based on a unique combination of assets and skills:
In October 2017, the OX-MPI development program of potent and selective mPGES-1 inhibitors was acquired from Orexo AB. From its early days, Gesynta Pharma was supported by Karolinska Institutet Innovation AB, Novo Nordisk Foundation, Swelife, and VINNOVA – Sweden’s Innovation Agency. Gesynta Pharma’s first financing round completed in February 2018, providing capital to conduct preclinical development and manufacture material needed to support a first clinical study.
In March 2019, a late-stage drug discovery project was acquired from Acturum Real Estate AB, including several potent and selective mPGES-1 inhibitors originating from AstraZeneca. In October 2020, GS-073 was nominated as a new candidate compound (CD) from the program and full development towards a First-in-Human clinical phase I study started.
A financing round in April 2019 with a consortium consisting of venture capital investors Industrifonden and Linc, together with a group of private life sciences investors provided funds for early clinical development of the lead candidate GS-248 from the OX-MPI development program. A First-in-Human clinical phase I study was initiated in June 2019 and results from the successfully completed study were presented at the June 2020 EULAR e-congress.
In July 2020, Gesynta Pharma raised SEK 190 million in a financing round led by Hadean Ventures to accelerate development of its first-in-class mPGES-1 inhibitor GS-248 for Raynaud’s phenomenon associated with systemic sclerosis while continuing work on other indications, such as endometriosis. Topline results from the phase IIa study were announced in September 2022. GS-248 was shown to be well tolerated, exhibited a favorable safety profile, and elicited a potent systemic inhibition of the target enzyme mPGES-1. However, no significant effects on vascular blood flow or Raynaud’s phenomenon could be demonstrated. For this reason, the company decided to focus the continued development of GS-248 on endometriosis.
Endometriosis is one of the key indications explored by the company. A preclinical proof-of-concept study was initiated in 2021. Results from this advanced preclinical disease model of endometriosis show that GS-248 markedly reduced the number of endometriosis lesions and had a positive impact on pain-related parameters and well-being. These data together with the previously demonstrated favorable clinical safety profile of GS-248 and the significant unmet medical need form the basis for the decision to initiate preparations for a phase II study in endometriosis, planned to start in 2023. A patent application was submitted in September 2022 covering the use of GS-248 in endometriosis.
By combining deep insights in the mechanism of a unique target with long-standing drug development competence, we exploit the medical and commercial opportunities in our portfolio of anti-inflammatory drug candidates.
Improving the lives of patients by realizing the potential of a unique target
Our four Core Values shape our company culture. They act as our guiding principle, ensuring we act and speak consistently across our business.
We keep promises, live up to expectations and take responsibility for our actions. We base our actions on integrity and high ethical standards and comply with laws and regulations. We are trustworthy in business as well as science. In everything we do, the patient is at the center of our endeavors.
We strive to provide better treatments for patients through extensive experience and knowledge. We aim for excellence in delivering on ambitious objectives.
We work in an open collaborative environment, supporting each other. We respect each other and enjoy both learning and teaching. We work in an industry of immense value to mankind and strive to pay forward to others in the field, as well as to patients and healthcare professionals.
Our passion is to help patients in need. Our curiosity and can-do attitude help us in developing better treatments for serious diseases. We are dedicated and courageous, and are driven by a clear sense of purpose.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in phase II, while GS-073 is about to enter phase I.